EP300 and pulmonary arterial hypertension: Notably, Chelladurai et al. demonstrated that EP300 inhibition by RNA interference or small-molecule compounds reduced PAH phenotypes and mesenchymal signatures in arterial fibroblasts and smooth muscle cells (Chelladurai et al. 2022).